[{"data":1,"prerenderedAt":188},["ShallowReactive",2],{"content-route-/en/research/evidence/vaginal-yeast-treatment-harms":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":16,"projection":137,"alternates":179},"target","/en/research/evidence/vaginal-yeast-treatment-harms","en-US",{"kind":8,"family":9,"sectionKeys":10},"evidence-map","guidance",[11,12,13,14,15],"claims","agreement-disagreement","changes","gaps","research",{"kind":8,"title":17,"description":18,"firstPublished":19,"evidenceAsOf":19,"lastUpdated":19,"changeNote":20,"firstLayer":21,"evidenceMap":51,"relations":67,"body":79},"Vaginal yeast treatment harms: an evidence map","A focused map of azole treatment withdrawal, local and systemic effects, and what FAERS report signals can and cannot establish.","2026-10-08","Published a focused harms evidence map; S004 adds contextual report signals only and changes no claim or practical treatment action.",{"question":22,"answer":23,"keyPoints":24,"confidence":28,"applicability":31,"nextSteps":38},"What does the evidence say about adverse effects with oral and intravaginal azoles for uncomplicated vaginal yeast infection?","The current claim remains supported, with moderate evidence and an elevated-risk safety status: treatment withdrawal for adverse effects was uncommon with either route; intravaginal products more often cause local burning or irritation, while oral azoles can cause systemic symptoms and important interactions. S004 adds unconfirmed FAERS signals only; it has no patient or exposure denominator and no verified report-level indication or route, so it changes neither the claim nor action.",[25,26,27],"Cochrane found high-certainty evidence that withdrawal because of adverse effects was uncommon with either route; evidence about total side-effect differences was low certainty.","CDC distinguishes local burning or irritation with topical agents from occasional systemic symptoms and clinically important interactions with oral azoles.","S004 adds spontaneous-report signals without verified VVC indication, route, or patient/exposure denominators; it does not establish incidence, causation, comparative safety, or a VVC-route-specific effect.",{"summary":29,"rationale":30},"Moderate confidence in the current route-harm claim for its defined population; S004 does not increase or reduce that confidence.","Cochrane found uncommon withdrawals with high-certainty evidence but low-certainty evidence for total side-effect differences. CDC describes the expected local-versus-systemic pattern. S004 is passive report signal detection without verified report-level indication or route.",{"appliesTo":32,"excludes":35},[33,34],"Adolescents and adults considering azole treatment for uncomplicated vulvovaginal candidiasis within the claim's defined population.","Readers distinguishing trial evidence and guideline descriptions from spontaneous FAERS reports.",[36,37],"Pregnancy and people whose conditions or medicines require an individualized interaction or contraindication assessment.","A prediction of an individual's chance of harm, a treatment ranking, or an interpretation of FAERS signals as incidence or causation.",[39,43,47],{"label":40,"action":41,"route":42},"Read the route comparison","Review the existing comparison for evidence and limits by outcome.","/en/treatments-evidence/topical-vs-oral-vaginal-yeast-treatment",{"label":44,"action":45,"route":46},"Check treatment guidance","See existing product-specific and locale-specific cautions in the treatment guide.","/en/treatments-evidence/vaginal-yeast-treatment",{"label":48,"action":49,"route":50},"Read the FAERS study summary","See the report counts, signals, and limits of the study itself.","/en/research/zhou-imidazole-faers-vvc-2024",{"claimIds":52,"agreements":54,"disagreements":57,"gaps":58,"changeRoutes":61,"researchRoutes":62,"reassessmentTrigger":66},[53],"uncomplicated-vvc-route-harm-tradeoff",[55,56],"The 2020 Cochrane review found only 3/4,637 participants stopped treatment because of adverse effects across 23 trials and rated evidence for the low withdrawal risk with either route as high certainty. It found low-certainty evidence for total side-effect differences: OR 1.04 (95% CI 0.84–1.29; 16 trials, 3,155 participants).","CDC guidance describes topical agents as usually causing no systemic side effects, while local burning or irritation can occur; oral azoles can occasionally cause nausea, abdominal pain, or headache, are rarely associated with abnormal liver-enzyme elevations, and can have clinically important drug interactions.",[],[59,60],"Total side-effect differences in the Cochrane review remained low certainty, and its included trials had high overall risk of bias; the review did not establish a clear difference in total side-effect counts by route.","S004 analyzed spontaneous reports without a patient or exposed-person denominator, verified report-level VVC indication or route, or causal adjudication. Its report counts and RORs cannot estimate incidence or an individual's probability of harm, compare treatment-route safety, or establish a route-specific effect.",[],[63],{"label":64,"description":65,"route":50},"FAERS report signals for four imidazoles","S004 describes unconfirmed report-level signals; missing patient/exposure denominators and unverified report-level indication and route mean it changes neither the claim nor practical action.","Reassess when a new systematic review, CDC guideline update, correction, or report-based study with verified indication and route plus appropriate exposure denominators materially changes this exact claim, or by 2027-01-15.",[68,72,75,77],{"group":69,"route":70,"label":71},"parent","/en/treatments-evidence","Treatments & evidence",{"group":73,"route":46,"label":74},"treatment","Vaginal yeast treatment",{"group":73,"route":42,"label":76},"Topical vs oral vaginal yeast treatment",{"group":15,"route":50,"label":78},"FAERS imidazole adverse-event report study",{"type":80,"value":81,"toc":133},"minimark",[82,109,115,121,127],[83,84,86,106],"content-section",{"section-key":11,"title":85},"Exact claim and current verdict",[87,88,89,93,94,97,98,101,102,105],"p",{},[90,91,92],"strong",{},"Exact claim:"," “For uncomplicated vulvovaginal candidiasis, stopping treatment because of adverse effects is uncommon with either oral or intravaginal azoles; intravaginal products more often cause local burning or irritation, whereas oral azoles can cause systemic symptoms and clinically important drug interactions.” ",[90,95,96],{},"Verdict:"," supported. ",[90,99,100],{},"Evidence level:"," moderate. ",[90,103,104],{},"Safety status:"," elevated-risk.",[87,107,108],{},"The 2020 Cochrane review found high-certainty evidence that stopping treatment because of adverse effects was uncommon with either route. It rated evidence for differences in total side effects as low certainty. CDC describes local burning or irritation with topical agents and occasional systemic symptoms, rare liver-enzyme elevations, and clinically important interactions with oral azoles. The claim applies only to its defined population; exact product cautions and locale actions remain with current authority sources.",[83,110,112],{"section-key":12,"title":111},"Where the sources agree and differ",[87,113,114],{},"The Cochrane review and CDC guidance support the same broad distinction: withdrawal due to adverse effects was uncommon in route-comparison trials, while the typical reported effects differ by route. Cochrane found only 3/4,637 participants withdrew because of adverse effects across 23 trials (high-certainty evidence); total side-effect differences remained uncertain (OR 1.04, 95% CI 0.84–1.29; 16 trials, 3,155 participants; low-certainty evidence). CDC notes local burning or irritation with topical products and possible systemic symptoms or interactions with oral azoles. These sources do not establish that one route has a lower overall harm rate for every person.",[83,116,118],{"section-key":13,"title":117},"Latest meaningful changes",[87,119,120],{},"S004 adds unconfirmed signals from spontaneous FAERS reports. Because its reports have no patient or exposure denominator and no verified report-level indication or route, this study changes neither the current claim, its moderate evidence level, its elevated-risk safety status, nor the practical action. No change route is listed.",[83,122,124],{"section-key":14,"title":123},"Limitations and gaps",[87,125,126],{},"The Cochrane review rated evidence about total side-effect differences as low certainty; its trial data do not resolve uncommon or long-term harms. S004 is not a treatment cohort: it lacks the number of people exposed to each drug, does not establish an indication or route for each report, and does not adjudicate causation. Its counts and reporting odds ratios cannot be interpreted as patient risk, incidence, comparative safety, or an effect specific to vaginal VVC treatment. The study also does not inform oral fluconazole, pregnancy-treatment advice, renal monitoring, or an individual's treatment.",[83,128,130],{"section-key":15,"title":129},"Selected research and practical contribution",[87,131,132],{},"The linked S004 summary describes its FAERS report selection, event counts, signal examples, funding, conflicts, and limitations. It contributes contextual, hypothesis-generating report data only. It does not support or challenge the current route-harm claim and does not change the action. The Cochrane review and CDC guidance remain the evidence basis for the existing claim.",{"title":134,"searchDepth":135,"depth":135,"links":136},"",2,[],{"sources":138,"claims":164,"safety":178},[139,148,156],{"sourceId":140,"title":141,"canonicalId":142,"canonicalUrl":143,"publisher":144,"sourceType":145,"publicationDate":146,"lastChecked":147},"cdc-sti-vvc-2021","Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm","US Centers for Disease Control and Prevention","guideline","2021-07-23","2026-07-15",{"sourceId":149,"title":150,"canonicalId":151,"canonicalUrl":152,"publisher":153,"sourceType":154,"publicationDate":155,"lastChecked":147},"cochrane-oral-vs-intravaginal-vvc-2020","Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)","doi:10.1002/14651858.CD002845.pub3","https://www.cochrane.org/evidence/CD002845_do-antifungal-medicines-vaginal-yeast-infections-thrush-work-better-if-taken-mouth-orally-or-placed","Cochrane","systematic-review","2020-08-24",{"sourceId":157,"title":158,"canonicalId":159,"canonicalUrl":160,"publisher":161,"sourceType":162,"publicationDate":163,"lastChecked":19},"zhou-imidazole-faers-vvc-2024","Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System","PMID:38914572; DOI:10.1038/s41598-024-63315-1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11196722/","Scientific Reports","observational-study","2024-06-24",[165],{"claimId":53,"exactClaim":166,"outcome":167,"population":168,"verdict":169,"evidenceLevel":170,"rationale":171,"safetyStatus":172,"evidenceAsOf":147,"lastUpdated":147,"status":173,"changeHistory":174,"sources":175},"For uncomplicated vulvovaginal candidiasis, stopping treatment because of adverse effects is uncommon with either oral or intravaginal azoles; intravaginal products more often cause local burning or irritation, whereas oral azoles can cause systemic symptoms and clinically important drug interactions.","treatment discontinuation and route-specific adverse-effect burden","adolescents and adults considering azole treatment for uncomplicated vulvovaginal candidiasis, excluding pregnancy and people whose medicines or conditions require an individualized interaction or contraindication assessment","supported","moderate","Cochrane found high-certainty evidence that withdrawal for adverse effects was uncommon with both routes but low-certainty evidence for total side-effect differences; CDC distinguishes local irritation from oral gastrointestinal symptoms, headache, rare liver-enzyme elevations, and important drug interactions. Exact product contraindications and locale actions remain authority-pack owned.","elevated-risk","active",[],[176,177],{"title":141,"canonicalId":142,"canonicalUrl":143,"publisher":144,"sourceType":145,"publicationDate":146,"lastChecked":147},{"title":150,"canonicalId":151,"canonicalUrl":152,"publisher":153,"sourceType":154,"publicationDate":155,"lastChecked":147},[],[180,183,186],{"rel":181,"hreflang":6,"href":182},"alternate","https://candipedia.org/en/research/evidence/vaginal-yeast-treatment-harms/",{"rel":181,"hreflang":184,"href":185},"pl-PL","https://candipedia.org/pl/research/dowody/dzialania-niepozadane-leczenia-grzybicy-pochwy/",{"rel":181,"hreflang":187,"href":182},"x-default",1791487498289]